Chugai Pharmaceutical (OTCMKTS:CHGCY) Announces Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its earnings results on Friday. The company reported $0.22 EPS for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.

Chugai Pharmaceutical Price Performance

CHGCY stock traded up $0.23 during midday trading on Friday, reaching $22.34. The company had a trading volume of 173,071 shares, compared to its average volume of 242,217. The firm has a 50-day moving average price of $23.46 and a 200-day moving average price of $26.43. The company has a market capitalization of $73.51 billion, a P/E ratio of 24.82 and a beta of 0.59. Chugai Pharmaceutical has a 1 year low of $19.50 and a 1 year high of $34.84.

Analysts Set New Price Targets

CHGCY has been the subject of a number of recent research reports. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.